Pharmafile Logo

Live Webinar: Poker face revealed: Using facial analysis to reveal deeper emotional insights

Thursday 28th February 2019, 10:00 EST / 15:00 GMT / 16:00 CET

Thursday 28th February 2019
10:00 EST / 15:00 GMT / 16:00 CET
Register now to secure your place » 

Does your expression give you away? According to psychologists, a lot of emotional information can be drawn from our facial expressions. Brief, involuntary flashes of emotion or ‘micro-expressions’ can reveal a lot about a person’s true feelings. As market researchers interested in the emotional responses driving people’s attitudes and behaviours, this information is invaluable but can often be difficult to obtain. One of the latest innovations in market research is facial analysis, which uses recognition software to detect a range of emotions in faces.

Register now to secure your place » 

Join us for this complimentary webinar event hosted in partnership with emotion measurement company, Affectiva, which has analysed over 5,000,000 faces and 24,000 adverts to understand how people respond to digital stimulus such as advertisements, websites and smartphone apps. We will demonstrate how, over the past several years, we’ve been using facial analysis in both qualitative and quantitative settings to delve further into respondents’ reactions to healthcare communications.

What are the key takeaways?

The theory
Learn more about the science and technology underpinning facial and emotional analysis.

Applications in healthcare MRX
Discover how we used facial analysis to deliver additional insights in a pharmaceutical setting.

Key considerations
Find out about the logistical challenges of using this methodology and how to overcome them.

Looking forwards
Explore future applications of facial analysis including integration with other technologies.

Gain answers to your key questions
At the end of the webinar there will be a live Q&A session. Start the conversation by submitting your questions in advance when you register.

Thursday 28th February 2019
10:00 EST / 15:00 GMT / 16:00 CET
Register now to secure your place »

This content was provided by Research Partnership

Company Details

 Latest Content from  Research Partnership 

Eyeforpharma Real World Evidence Conference Round up 2018

Earlier this month, APAC Director Pei Li Teh attended Asia’s 11th Eyeforpharma conference in Tokyo, Japan with a focus on Real World Evidence (RWE)This year has seen a turning point...

EphMRA Annual Conference 2018

Visit us on stand number 20

Connected Patients – Adopting a patient-centric approach in emerging markets

The concept of patient centricity and putting the patient at the heart of care is being widely adopted by the healthcare industry – the general consensus being that it’s going...

Combination therapies in oncology: The benefits of integrated insights

14 June 2018 11am EDT | 8am PDT | 4pm BST | 5pm CE

Intellus round up 2018

Earlier this month, US President Harriet Kozak and Emerging Markets Director Rachel Howard attended the inaugural Intellus Worldwide Summit in Philadelphia

Janssen & Research Partnership win prestigious BHBIA Best Business Impact award

We are delighted to announce that Janssen and Research Partnership have won the BOBI (Best of Business Intelligence) Award in the Best Business Impact category at the BHBIA annual conference in London for our collaborative market research...

How published research underpinned a cancer therapy awareness campaign

Our client markets a product for Oral Mucositis (OM) - a side effect of cancer treatment - and wanted to better understand the disease and treatment challenges faced by both...

How integrated insights supported a biologic launch strategy across multiple indications

Our client is launching a new biologic in dermatology across indications and needed to understand the market, including the patient pool, treatment landscape, potential uptake and pricing opportunity for their...

How a hybrid approach delivered fast insights to feed into an oncology product’s adoption strategy

Our client wanted to quantify how ovarian cancer patients are managed prior to product launch, but also needed to understand why patients do or do not receive key diagnostic tests...